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Cross-target biochemical experiments demonstrated that some molecules display an ample 
spectrum of biological activities which are therapeutically effective. In this regard we 
investigated the chemical space of the following targets GSK3, DPP IV and PPAR gamma since 
the DPP IV inhibitors, and PPAR gamma agonists are used to treat diabetes miellitus of type 2. 
Nevertheless, GSK-3 inhibitors have shown therapeutic potential for insulin resistant type-2 
diabetes, the drug market does not register yet an inhibitor of GSK-2 for therapeutical use. The 
ChEMBL homo sapiens assay data for GSK-3, DPP IV and PPAR gamma were assembled into 
are database including 7599 compounds. GSK-3 assay comprise 2497 compounds, from which 
1889 are unique divided into 428 chemotypes. DPP IV register 3482 compounds and 3026 were 
unique sharing 510 chemotypes. PPAR gamma incldes 1620 agonists from which 1333 are 
unique partitioned into 264 chemotypes. The chemical space of GSK3, DPP IV and PPAR 
gamma share 12 chemotypes, GSK3 and DPP IV share 30 chemotypes, DPP IV and PPAR 
gamma share 13 chemotypes, whereas GSK3 and PPAR gamma share 17 chemotypes. The 12 
chemotypes active on all three proteins were superposed to develop a common pharmacophore 
which will be further used to identify novel chemotyes with potential biological activity. 
 
Introduction 
In this study we investigated the chemical space of the following targets: Glycogen Synthase 
Kinase-3 (GSK-3)[1] and Dipeptidyl Peptidase IV (DPP IV) inhibitors [2] and Peroxisome 
Proliferator-Activated Receptor Gamma (PPARγ) [3] agonists which are used to treat diabetes 
miellitus of type 2. 
Sitagliptin (original brand name Januvia) is a highly selective DPP IV inhibitor, used in patients 
with type 2 diabetes mellitus to improve glycemic control in combination with metformin or a 
PPARγ agonist (e.g., thiazolidinediones)[2]. 
Our goal was to detect shape similar compounds with Sitagliptin (2R)-4-oxo-4-[3-
(trifluoromethyl)-5,6-dihidro[1,2,4]triazolo[4,3-A]pirazin-7(8H)-yl]-1-(2,4,5-
trifluorophenyl)butan-2-amine (PDB code: 4FFW_715) conformer cocrystallized with DPP IV. 
To accomplish our goal aRapid Overlay of Chemical Structures(ROCS) search was performed 
using the above mentioned sitagliptin conformation.Further we investigate the commom 
pharmacophore point to identify a possible common interaction pattern. 
 
Figure 1.The structure of sitagliptin DPP IV  inhibitor used as query 






The dataset used in our study was downloaded from the ChEMBL [4] database, to obtain 
bioactive compounds on GSK-3, DPP IV and PPAR gamma, whch asseembled resulted in 7599 
compounds. 
In the fisrt step the active compounds were filtered for duplicates using InstantJChem [5] 
software  resulting 6248 unique compounds from which 1889 active compounds were for GSK-3, 
3026 active compounds for DPP IV, and 1333 active compounds for PPAR gamma. 
In the second step these unique compounds were divided into 428 chemotypes for GSK-3, 510 
chemotypes for DPP IV and 264 chemotypes for PPAR gamma using Bemis Murko frameworks 
from InstantJChem [5] software. 
In the third step were found 12 common chemotypes for the all proteins from where we extracted 
12 active compounds with the highestIC50. 
Thesitagliptin conformation was downloaded from the RCSB Protein Data Bank [6] and the bond 
orders were checked. 
The input for ROCS [7] analysis were the conformers of the 12 compoundswhose affinities were 
measured against all hereby investigated proteins which were generated with Omega version 
2.3.2 from OpenEye [8] package using by default settings (RMSD = 0.8 Ǻ, a energy window of 
10 kcal, maximum output conformers 400. 
 
Results and Discussions 
The shape similarity search with ROCS has been proved to produce fast and reliable results that 
guarante good quality alignment.  
All the conformes were overlaid, over the X-ray structure (4FFW_715) [4] ) and thirteen 
similarity functions TanimotoCombo, ShapeTanimoto, ColorTanimoto, FitTverskyCombo, 
FitTversky, FitColorTversky, RefTverskyCombo, RefTversky, RefColorTversky, ScaledColor, 
ComboScore, ColorScore, Overlap implemented in ROCS were calculated [7-10]. 
The minimal, maximal and mean values of the most important similarity coefficients resulted 
from the similarity searches against the query (Figure 1) are listed in Table 1.  
 











min 0.479 0.338 0.13 0.6 
max 1.531 0.848 0.71 1.558 
average 0.72051 0.485677 0.316521 0.818698 
*TC-TanimotoCombo, ST-ShapeTanimoto, SC-ScaledColor, CS-ComboScore 
 
The distributions of the minimal, maximal and mean values of important tanimoto similarity 
functions are shown in Figure 2 





Figure 2. The distribution of the Tanimoto Combo, Shape Tanimoto, Scaled Color and Combo 
Score 
 
The first 10 molecules ranked by ROCS were DPP IV inhibitors bearing different substituents 
(Figure 3). As expected, it can be observed (Figure 3) that these compounds align very well to the 
sitagliptin conformation. 
 
Figure 3. Alignment of the top 10 hits (line) to the RX ligand (stick) [11]. 
 
a  b  
Figure 4. Superposition of the X-ray structure of the ligand (stik) and the corresponding best 
overlayed conformation for CHEMBL1779688 (line) (a) and CHEMBL381806 (line)(b)[11]. 
 
The best superposition compounds whose corresponding shape TanimotoCombo is of 1.531 
CHEMBL1779688 (Figure 4a) and ComboScore (including Shape + ColorScore) values (1.347) 




corresponds CHEMBL381806 (Figure 4b) [11].These values are good enough to suggests 
structural similarity, but also a certain degree of scaffold hopping. 
 
Conclusions 
The 7599 compounds downoladed from ChEMBL database with experimentally determined IC50 
were involved in our final study.The ROCS analysis provided 12 active compounds for all tree 
protein with common chemical space.The 12 compounds active on all three proteins were 
superposed to develop a common pharmacophore which will be further used to identify novel 
chemotyes with potential biological activity. 
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